Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CMD-193
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CMD-193 is an antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody (Hu3S193) targeting the Lewis Y (LeY) antigen, conjugated to the cytotoxic agent calicheamicin. The LeY antigen is expressed on various tumor cells. Calicheamicin is a potent enediyne antibiotic that induces DNA double-strand breaks, leading to cell death. CMD-193 was developed for its potential antineoplastic activity in cancers expressing the LeY antigen. The drug was initially developed by Wyeth and reached phase 1 clinical trials for advanced solid tumors but development has since been discontinued[1][2][3][6].
- Other names
- Hu3S193-calicheamicinHu-3S193-calicheamicinHu 3S193-calicheamicinimmunotoxin CMD-193
02
Targets
LeY (Lewis Y antigen)DNA
Beyond the preview
Go deeper on CMD-193.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CMD-193.